A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

INTRODUCTION: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported to have a lower risk of pneumonitis than program...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Iwasawa, Shunichiro, Sato, Yuki, Harada, Toshiyuki, Kubota, Kaoru, Tokito, Takaaki, Okamoto, Isamu, Furuya, Naoki, Yokoyama, Toshihide, Hosokawa, Shinobu, Iwasawa, Tae, Yamanaka, Takeharu, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446731/
https://www.ncbi.nlm.nih.gov/pubmed/32858235
http://dx.doi.org/10.1016/j.jtho.2020.08.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446731/
https://www.ncbi.nlm.nih.gov/pubmed/32858235
http://dx.doi.org/10.1016/j.jtho.2020.08.018

Ejemplares similares